Meet Our Team

Monument Tx is led by a highly experienced team of executives with direct experience designing and managing hundreds of cognitive clinical trials.

Monument Therapeutics JB
Dr Jenny Barnett, Chief Executive Officer
Jenny was Chief Scientific Officer at Cambridge Cognition where she led clinical trial, healthcare and R&D functions before spinning out Monument Therapeutics.  She has an MA in Experimental Psychology from Oxford University, a PhD in the epidemiology of schizophrenia from the University of Cambridge, and completed post-doctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She is the author of more than 70 papers, six patents, and two pop science books and is an honorary member of the University of Cambridge Department of Psychiatry.
Monument Therapeutics KG

Dr Kiri Granger, Chief Scientific Officer
Kiri is an internationally-recognised expert in the design of clinical trials for CNS disorders, particularly schizophrenia. As Director of Neuroscience at Cambridge Cognition, Kiri provided consultancy to over 50 drug development companies on more than 100 clinical trials and was the lead scientist on a number of successful programmes. Kiri chaired the ICSTM working group on schizophrenia clinical trials and is currently an Assistant Professor at the University of Nottingham, Department of Psychology where she is involved in on-going collaborations in schizophrenia and anxiety disorders.

Monument Therapeutics SC

Sheryl Caswell, Head of Development
Sheryl graduated in Medical Microbiology and has since worked exclusively in the clinical research arena for over twenty five years .  She has successfully led and managed clinical development programmes across a range of therapeutic indications, with a recent focus on working in small biotech companies within a small team designing and conducting development programmes for products at an early phase of development.

Monument Leadership Photos Final-06

Dr Mark Treherne, Chair
Mark has been actively involved in the biopharmaceutical industry for over 25 years and previously led the neurodegeneration research group at Pfizer’s research facility in Sandwich. To date he has helped to raise over £300 million for early-stage biotechnology companies and out-licensed therapeutic assets for upfront payments, milestones and royalties exceeding £1.5 billion. Mark has a PhD in Pharmacology from the University of Cambridge.

Paula Moran

Dr Paula Moran, Scientific Consultant
Paula is a pioneering research scientist and an honorary Associate Professor at the University of Nottingham. Following a PhD from the National University of Ireland she has had academic roles at the Institute of Psychiatry, Kings College London and University of Nottingham, where she led collaborations with several pharmaceutical industry partners. She is best known for her translational research on abnormal information processing.

Dr Julian Gilbert
Julian brings deep expertise in the development and commercialising of repurposed compounds, having been co-founder and CEO of Acacia Pharma.  During his time at Acacia, Julian raised approximately £100 million in private and public funding, leading its flotation on Euronext in 2018 which enabled the company to gain approval and launch BARHEMSYS® in the US.  Prior to this, Julian was co-founder and Commercial Director of Arakis, a specialist pharmaceutical repurposing company that was sold to Sosei in 2005 for £107 million, having licensed Seebri®/Ultibro® to Novartis.  In his more than 30 years of commercial and technical experience in the pharmaceutical industry, Julian has also worked at Chiroscience, Mundipharma International, BTG and GSK.  Julian holds a degree in pharmacy and a PhD in pharmaceutics from the University of Nottingham.

Richard Bungay
Richard is currently Interim Chief Executive Officer of Diurnal Group plc, an AIM listed speciality pharmaceutical company. Richard has over 25 years’ experience in senior finance and strategic roles within the pharmaceutical and biotechnology sector. His prior experience includes CFO and COO of Mereo BioPharma, CFO of Glide Technologies, CFO of Verona Pharma, CEO/CFO of Chroma Therapeutics, Director of Corporate Communications and Strategic Planning at Celltech and Finance Director of the Respiratory and Inflammation therapy area at AstraZeneca. Richard is also a Non-Executive Director of Cambridge Cognition. He qualified as a Chartered Accountant with Deloitte and has a first class degree in Chemistry from Nottingham University.

Steve Plant
Steve is an experienced Finance Director specialising in working with early-stage SMEs in the UK tech/healthcare sector.
He qualified as a Chartered Accountant in Manchester with KPMG and after qualifying joined a UK-wide retail business where he held a number of roles. He then moved into international retail as finance director for new business start-ups in Russia and India. On returning to the UK Steve has held a variety of Financial Director roles in customer facing businesses across a broad range of industry sectors.
Steve’s portfolio career has seen him assist a range of SMEs in raising significant investment and works closely with business founders, VCs, and angel investors to ensure the business is moving in the right direction.